The global sepsis diagnostics market is expected to record a CAGR of 8.1% between 2023 and 2033. In 2023, the market is estimated to be valued at US$ 561.2 million. The valuation is expected to cross US$ 1.2 billion by 2033.
Factors that are expected to drive the market growth are:
During the COVID-19 pandemic, there was an increase in people who were getting hospitalized. This led to a surge in the cases of sepsis as well. Thus, an increasing prevalence of hospital-borne diseases, along with the prevalence of chronic diseases across age groups, might surge the growth of the market.
Centers for Disease Control and Prevention states that 1 in 3 people who have died in hospital had sepsis. This has led to a surging need for diagnosing sepsis at the earliest, which has made healthcare workers more aware.
The introduction of technologically advanced diagnostic solutions that offer real-time insights and monitor patient health, along with the growth of sepsis, is contributing to the growth. In addition, factors such as the high prevalence of sepsis, and increasing awareness, are expected to significantly fuel the market growth over the forecast period.
The increasing prevalence of life-threatening diseases around the globe, especially in developing regions such as the Asia Pacific and the Middle East & Africa, might propel growth. Moreover, the integration of technology in testing and diagnosing, along with offering treatment, is shaping the landscape for the sepsis diagnostics market.
The difficulty in diagnosing sepsis has led to research and development by healthcare sectors and research institutes. Sepsis is a very difficult condition to diagnose. This had led to the risk of mortality rate increasing by 7.6%, with a delay of even 1 minute in antibiotic administration in septic shock patients with hypertension. Thus, the scope of development of the sepsis diagnostics market is expected to increase in the upcoming years.
Thus, increasing the need for the rapid diagnosis of sepsis to reduce the delay of antibiotic therapy among patients with sepsis has increased. Increasing regulatory approval and the introduction of technologically advanced diagnostic solutions are expected to be the prominent factors facilitating the market growth. Manufacturers of sepsis diagnostic are expanding their product offering in point of care technology that helps in detecting sepsis and reducing the overall turnaround time.
North America is expected to hold the dominant market share during the forecast period. The availability of advanced healthcare facilities, the increasing geriatric population, and chronic diseases is expected to propel the market growth.
| Attributes | Value |
|---|---|
| Market Value (2022) | US$ 520.8 million |
| Market Expected Value (2023) | US$ 561.2 million |
| Market Forecast Value (2033) | US$ 1.2 billion |
| Market Expected CAGR (2023 to 2033) | 8.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Several people suffering from various ailments, along with hospital-acquired diseases, are increasing the cases of sepsis. This, in turn, is creating lucrative opportunities for the sepsis diagnostics market. The technological upgrade of the existing healthcare infrastructure is expected to fuel the growth. This is visible in the form of a comparison between historical CAGR and anticipated CAGR. While the historical CAGR for the market was 7.5%, the anticipated CAGR is 8.1%.
Short Term (2023 to 2026):HAIs can result in sepsis in immunocompromised people, the elderly, and those with chronic conditions. Annually, the CDC estimates that more than 1,000,000 cases of sepsis occur among hospitalized patients in the United States (Source: CDC, 2018). With the increasing growth of HAIs globally, demand for sepsis diagnostics devices is projected to expand during this period
Medium Term (2026 to 2029): During this timeframe, we might witness an increase in the number of chronic diseases owing to various factors like lifestyle diseases, geriatric population, etc. Almost 500 million people are at risk of developing lifestyle diseases by 2030. This might increase the sales of sepsis diagnostics devices during this term.
Long Term (2029 to 2033): During this period, the market is expected to be driven by technological innovation. In January 2023, the Food and Drug Administration in the United States cleared Cytovale IntelliShop sepsis test, which is believed to be the first in the new class of emergency department-focused diagnostic tools. In the future, we might see more such innovations shaping the marketplace.
The global sepsis diagnostics market is expected to grow due to increased research and development efforts. Using a microelectrode biosensor, the sepsis diagnostic devices identify interleukin-6, a protein biomarker, in less than three minutes.
Hospital-acquired infections (HAIs), also known as nosocomial infections, are a leading source of morbidity and death around the world. Urinary tract infections, pneumonia, and sepsis are the most frequent hospital-acquired infections. Sepsis molecular diagnostics among hospitalized patients in the United States has been increasing at an annual rate of 8.7%. With the significant growth of HAIs throughout the world, the market for sepsis diagnostic devices is projected to surge in the future years.
Principal Consultant
According to the National Institutes of Health, a molecular diagnostic test can cost between US$ 300 and US$ 3,000. This is much more expensive than blood culture tests, which can cost as little as US$ 28 to US$ 35.
Although sepsis diagnostics companies are concentrating on developing automated diagnostic instruments, academic research laboratories cannot afford such systems. This is because of the funding problems and the absence of required infrastructure. This is becoming a significant hurdle to the market's growth for sepsis diagnostics devices.
Sepsis is a potentially fatal illness that must be detected and treated as soon as possible by trained healthcare experts. Unfortunately, the global scarcity of competent professionals is a big problem. Barely half of the patients with severe sepsis transferred by the EMS system are accompanied by a paramedic. The shortage of qualified paramedics has an impact on all phases of patient care, including sepsis awareness.
| Region | North America |
|---|---|
| Country | United States |
| CAGR (2023 to 2033) | 7.9% |
| Region | Europe |
|---|---|
| Country | United Kingdom |
| CAGR (2023 to 2033) | 6.9% |
| Region | Asia Pacific |
|---|---|
| Country | China |
| CAGR (2023 to 2033) | 9.2% |
| Region | Asia Pacific |
|---|---|
| Country | Japan |
| CAGR (2023 to 2033) | 4.5% |
| Region | Asia Pacific |
|---|---|
| Country | India |
| CAGR (2023 to 2033) | 11% |
The United States is the leading market in North America. In 2019, the geriatric population in the country was 54.1 million. By 2040, the population is expected to surge past 80.8 million, which forms a considerable chunk of the overall population. According to a report, more than 40% of sepsis cases occur in older patients.
| Attributes | Details |
|---|---|
| United States Market Expected Size (2033) | US$ 342 million |
| United States Market Absolute Dollar Growth | US$ 181.8 million |
| CAGR % 2017 to 2022 | 7.5% |
As per the data available from the Centers for Disease Control and Prevention, nearly 1.7 million adults in the United States develop sepsis. The scope for sepsis diagnostics is also expected to surge, because there is an increase in people suffering from chronic diseases in the United States.
The United Kingdom market is expected to be driven owing to a huge amount of patients suffering from chronic kidney disease. As per kindneycareuk, more than 3.5 million people are suffering from the disease. A lot of patients who suffer from kidney disease develop complications due to the non-suitability of drugs, because of which they develop sepsis.
| Attributes | Details |
|---|---|
| United Kingdom Market Expected Size (2033) | US$ 52 million |
| United Kingdom Market Absolute Dollar Growth | US$ 25.4 million |
| CAGR % 2017 to 2022 | 5.8% |
There are also cases of cardiovascular disease and respiratory diseases in the United Kingdom, and the severity is more in the case of geriatric patients. There are a lot of people who develop complications because of lifestyle diseases, and when they are admitted, they develop complications owing to sepsis.
Based on the reports, China has been reporting close to 13,000 COVID-19 deaths every week. Severe COVID-19 leads to viral sepsis. Breathlessness and high temperature while contracting COVID-19 had led to the development of sepsis in extreme cases. This can be attributed to the fact that more than 33.6% of the patients who were admitted to the ICU in mainland China developed sepsis.
| Attributes | Details |
|---|---|
| China Market Expected Size (2033) | US$ 146.6 million |
| China Market Absolute Dollar Growth | US$ 86 million |
| CAGR % 2017 to 2022 | 8.8% |
China is also home to the soaring diabetic patients in the world. As per a research report, nearly 21% of patients who suffer from sepsis are diabetic patients. The researchers are of the view that diabetes slowly weakens the organs of the human body, and due to the lack of capacity to operate, sepsis develops.
Cancer is believed to be the leading cause of death in Japan. Based on the research reports, one in four deaths is caused because of cancer. After chemotherapy, patients are at a risk of developing highly infectious diseases, which leads to the development of sepsis.
| Attributes | Details |
|---|---|
| Japan Market Expected Size (2033) | US$ 47.7 million |
| Japan Market Absolute Dollar Growth | US$ 17 million |
| CAGR % 2017 to 2022 | 3.8% |
After cancer, CVD is believed to be one of the most frequent causes of admission to the hospital. After the patient is administered certain kinds of drugs, due to the side effects, the patient develops sepsis. All these factors are expected to surge the market growth of sepsis diagnostics. Moreover, the sedentary lifestyle has led to rise in lifestyle diseases, which has surged the adoption of sepsis diagnostics devices.
Pollution has been on the rise in India. Owing to vehicular emissions and increasing construction activities, there has been an increase in chronic inflammatory lung disease and asthma. Asthma and chronic inflammatory lung disease lead to the weakening of the lungs, as a result of which the patient is susceptible to sepsis.
| Attributes | Details |
|---|---|
| India Market Expected Size (2033) | US$ 96.5 million |
| India Market Absolute Dollar Growth | US$ 62.6 million |
| CAGR % 2017 to 2022 | 11.5% |
Renal disease is also quite common in India. The prevalence of diabetes and hypertension mainly leads to the development of sepsis as a result of renal disease. Owing to an increase in stress levels in various age groups, there have been surging incidences of stroke as well. While the patients undergo stroke treatment, they may develop hospital-acquired infections, which leads to the development of sepsis.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Segment | Product Type |
|---|---|
| Attributes | Blood Culture Media |
| CAGR (2017 to 2022) | 5.5% |
| CAGR (2023 to 2033) | 5.9% |
| Segment | Method |
|---|---|
| Attributes | Conventional Diagnostics |
| CAGR (2017 to 2022) | 6.3% |
| CAGR (2023 to 2033) | 5.6% |
The blood culture media is expected to be the most preferred product type. It accounted for the leading revenue of more than 46% in 2022. The blood culture media is considered to be the most cost-effective form of product type. The convenience offered by this method is high as compared to other forms.
The researchers are of the view that the instruments segment is expected to showcase promising growth during the forecast period. This can be attributed to the rising awareness in the general populace about the increasing rate of surgical procedures.
The conventional method is expected to hold a sizable market share. Though the automated diagnostic tests are more accurate in predicting sepsis-causing pathogens, their high-cost acts as a barrier. While the conventional method costs US$ 28 to US$ 30, the cost for an automated diagnostic method can be up to US$ 3,000.
However, increasing healthcare spending in developed and developing regions boosts the demand for automated sepsis diagnosis in the years ahead. Another reason for predicting positive growth for the automated molecular sepsis diagnostics market is the shortage of trained healthcare professionals.
The newbies in the market have come up with an extracorporeal therapy for sepsis treatment. They make use of protein immobilization and formulation to develop therapies that target specific immune modulators. They also plan to make extracorporeal therapy compatible with the existing intensive care unit equipment.
MediSieve: The start-up has developed a magnetic filter that selectively removes targeted substances from the patient’s bloodstream. The technology developed by them makes use of targeted magnetic particles that bind to bacteria and other pathogens. The filter would capture these pathogens at the end of the blood loop, before flowing back to the body. In July 2021, MediSieve raised US$ 1.8 million from 24Haymarket to pursue its trials.
The key players operating in the market focus on developing products, which are a blend of innovation and reliance. In August 2022, Biomerieux announced that its SPECIFIC REVEAL Rapid AST Systems received the Breakthrough Device Resignation from the United States Food and Drug Administration. The designation is deserved for medical devices that offer significant advantages over existing cleared alternatives.
Key developments in the market are:
| Company | Description |
|---|---|
| Biomerieux | Biomerieux has been the world leader in the field of in vitro diagnostics. The solutions that Biomerieux envisions, develops, and manufactures, are the key to enabling healthcare professionals to make confident decisions. The company sustains a robust business model that allows it to invest in value creation. The company fosters transparent and ethical dialogue with the healthcare ecosystem to advance diagnostics. |
| T2 Biosystems | T2 Biosystems has always believed in saving lives and improving healthcare by empowering clinicians to get patients on the right therapy. The T2 Magnetic Resonance is a game-changing detection technology that is all about providing modern solutions. The company is also meant for its pipeline of future products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. |
| DANAHER Corporation | DANAHER Corporation is a science and technology innovator committed to helping customers solve complex challenges and improve their quality of life. The ground-breaking services offered by the company have been transforming the field of life sciences, water quality, and product identification. This is being done by ensuring the freshness and safety of food, pharmaceuticals, and consumer goods. |
Other key players profiled: BECTON, DICKINSON, AND COMPANY, and Luminex
The growth potential of this market is 8.1% through 2033.
From 2018 to 2022, the global market exhibited a 7.5% CAGR.
Limited funding and infrastructure hinder academic labs, impeding market growth.
China is likely to expand 9.2% CAGR from 2023 to 2033.
Investment in research and development drives the market growth.
1. Executive Summary | Sepsis Diagnostic Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2017 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033
5.3.1. Blood Culture Media
5.3.2. Instrument
5.3.3. Assays & Reagents
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017 to 2022
5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033
6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Method
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Method, 2017 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Method, 2023 to 2033
6.3.1. Conventional Diagnostics
6.3.2. Automated Diagnostics
6.4. Y-o-Y Growth Trend Analysis By Method, 2017 to 2022
6.5. Absolute $ Opportunity Analysis By Method, 2023 to 2033
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Pathogen
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Pathogen , 2017 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Pathogen , 2023 to 2033
7.3.1. Gram-negative Bacterial Sepsis
7.3.2. Gram-positive Bacterial Sepsis
7.3.3. Fungal Sepsis
7.3.4. Other Pathogens
7.4. Y-o-Y Growth Trend Analysis By Pathogen , 2017 to 2022
7.5. Absolute $ Opportunity Analysis By Pathogen , 2023 to 2033
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Technology
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2017 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2023 to 2033
8.3.1. Microbiology
8.3.2. Molecular Diagnostics
8.3.3. Immunoassays
8.3.4. Other Technology
8.4. Y-o-Y Growth Trend Analysis By Technology, 2017 to 2022
8.5. Absolute $ Opportunity Analysis By Technology, 2023 to 2033
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. Asia Pacific Excluding Japan
9.3.5. Japan
9.3.6. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Product Type
10.2.3. By Method
10.2.4. By Pathogen
10.2.5. By Technology
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Method
10.3.4. By Pathogen
10.3.5. By Technology
10.4. Key Takeaways
11. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Product Type
11.2.3. By Method
11.2.4. By Pathogen
11.2.5. By Technology
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Method
11.3.4. By Pathogen
11.3.5. By Technology
11.4. Key Takeaways
12. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Product Type
12.2.3. By Method
12.2.4. By Pathogen
12.2.5. By Technology
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Method
12.3.4. By Pathogen
12.3.5. By Technology
12.4. Key Takeaways
13. Asia Pacific Excluding Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. India
13.2.1.3. Thailand
13.2.1.4. Singapore
13.2.1.5. Australia
13.2.1.6. Rest of Asia Pacific Excluding Japan
13.2.2. By Product Type
13.2.3. By Method
13.2.4. By Pathogen
13.2.5. By Technology
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Method
13.3.4. By Pathogen
13.3.5. By Technology
13.4. Key Takeaways
14. Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.2. By Product Type
14.2.3. By Method
14.2.4. By Pathogen
14.2.5. By Technology
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Type
14.3.3. By Method
14.3.4. By Pathogen
14.3.5. By Technology
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of Middle East and Africa
15.2.2. By Product Type
15.2.3. By Method
15.2.4. By Pathogen
15.2.5. By Technology
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product Type
15.3.3. By Method
15.3.4. By Pathogen
15.3.5. By Technology
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Product Type
16.1.2.2. By Method
16.1.2.3. By Pathogen
16.1.2.4. By Technology
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Product Type
16.2.2.2. By Method
16.2.2.3. By Pathogen
16.2.2.4. By Technology
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Product Type
16.3.2.2. By Method
16.3.2.3. By Pathogen
16.3.2.4. By Technology
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Product Type
16.4.2.2. By Method
16.4.2.3. By Pathogen
16.4.2.4. By Technology
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Product Type
16.5.2.2. By Method
16.5.2.3. By Pathogen
16.5.2.4. By Technology
16.6. United kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Product Type
16.6.2.2. By Method
16.6.2.3. By Pathogen
16.6.2.4. By Technology
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Product Type
16.7.2.2. By Method
16.7.2.3. By Pathogen
16.7.2.4. By Technology
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Product Type
16.8.2.2. By Method
16.8.2.3. By Pathogen
16.8.2.4. By Technology
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Product Type
16.9.2.2. By Method
16.9.2.3. By Pathogen
16.9.2.4. By Technology
16.10. China
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Product Type
16.10.2.2. By Method
16.10.2.3. By Pathogen
16.10.2.4. By Technology
16.11. India
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Product Type
16.11.2.2. By Method
16.11.2.3. By Pathogen
16.11.2.4. By Technology
16.12. Thailand
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Product Type
16.12.2.2. By Method
16.12.2.3. By Pathogen
16.12.2.4. By Technology
16.13. Singapore
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Product Type
16.13.2.2. By Method
16.13.2.3. By Pathogen
16.13.2.4. By Technology
16.14. Australia
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Product Type
16.14.2.2. By Method
16.14.2.3. By Pathogen
16.14.2.4. By Technology
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Product Type
16.15.2.2. By Method
16.15.2.3. By Pathogen
16.15.2.4. By Technology
16.16. GCC Countries
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Product Type
16.16.2.2. By Method
16.16.2.3. By Pathogen
16.16.2.4. By Technology
16.17. South Africa
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Product Type
16.17.2.2. By Method
16.17.2.3. By Pathogen
16.17.2.4. By Technology
16.18. Israel
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Product Type
16.18.2.2. By Method
16.18.2.3. By Pathogen
16.18.2.4. By Technology
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Product Type
17.3.3. By Method
17.3.4. By Pathogen
17.3.5. By Technology
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. BIOMÉRIEUX
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. BECTON, DICKINSON, AND COMPANY
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. DANAHER CORPORATION
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. T2 BIOSYSTEMS
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. LUMINEX
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. F. HOFFMANN-LA ROCHE AG
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. THERMO FISHER SCIENTIFIC
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. BRUKER CORPORATION
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. ABBOTT LABORATORIES
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. QUIDEL CORPORATION
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Sepsis Diagnostics Market
